Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
An NCI-sponsored trial characterizes individuals and families at high risk of hematologic cancers, focusing on conditions including Waldenst…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) [Phase 2]
This document provides an update on a Phase 2 clinical trial evaluating the combination of mosunetuzumab with pirtobrutinib in patients with…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies [Phase 1, Phase 2]
This is a Phase 1/2 dose-escalation and expansion study of BGB-16673 in patients with various B-cell malignancies and is currently recruitin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers [Phase 1]
This document outlines an ongoing Phase 1 trial evaluating NKX019, an allogeneic CAR NK cell therapy, in adults with B-cell cancers includin…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
This observational study investigates cardiac arrhythmias in patients treated with BTK inhibitors or venetoclax in chronic lymphocytic leuke…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial update for BGB-16673, a BTK-targeted protein degrader, in Chinese participants with various B-cell malignan…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
This clinical trial status update indicates an ongoing natural history study of Monoclonal B-Cell Lymphocytosis, chronic lymphocytic leukemi…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) [Phase 2]
A Phase 2 trial evaluating oral venetoclax in adults with relapsed or refractory Waldenström macroglobulinemia and lymphoplasmacytic lymphom…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) [Phase 2]
Phase 2 trial update on the efficacy and safety of Nemtabrutinib (MK-1026) in hematologic malignancies, including Waldenström macroglobuline…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Long-term Extension Study of PCI-32765 (Ibrutinib) [Phase 3]
Phase 3 long-term extension study of ibrutinib (PCI-32765) in chronic lymphocytic leukemia/small lymphocytic lymphoma and other B-cell malig…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma [Phase 2]
An ongoing Phase 2 clinical trial compares the combination of venetoclax and rituximab against the usual treatment (ibrutinib plus rituximab…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM [Phase 2]
A Phase 2 trial evaluating Zanubrutinib, Bendamustine, and Rituximab in previously untreated Waldenström macroglobulinemia is currently recr…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
A clinical trial registry update from Dana-Farber Cancer Institute notes a study involving questionnaires and tissue banking for multiple my…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies [Phase 1]
Phase 1 clinical trial evaluating Sonrotoclax (BGB-11417), a Bcl-2 inhibitor, in participants with mature B-cell malignancies. The study is …
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 clinical trial evaluating Rituximab plus Bendamustine and ibrutinib (PCI-32765) in relapsed DLBCL, mantle cell lymphoma, and various…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]
Phase 1 study evaluating NX-2127 in adults with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom [Phase 2]
Phase 2 clinical trial update for CLR-131 in select B-cell malignancies, with expansion into Waldenström macroglobulinemia. The study status…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. [Phase 4]
BLOOD-dose is a Phase 4 platform trial evaluating dose optimization in hematologic diseases, with Waldenström macroglobulinemia and multiple…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia [NA]
This clinical trial studies the phenotypic and functional characteristics of bone marrow mesenchymal stem cells in Waldenström macroglobulin…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Epcoritamab in Previously Treated WM [Phase 2]
Epcoritamab is being studied in a Phase 2 trial for patients with Waldenström macroglobulinemia who have received prior treatment; the study…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma [Phase 2]
Phase 2 trial evaluating the efficacy and safety of Lisaftoclax (APG-2575) as a monotherapy in indolent lymphomas, including Waldenström mac…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Nemtabrutinib, Bortezomib, and Rituximab for WM [Phase 2]
Phase 2 clinical trial at Seoul National University Hospital evaluating nemtabrutinib in combination with bortezomib and rituximab for Walde…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
An observational study evaluating the efficacy and safety of zanubrutinib in participants with Waldenström macroglobulinemia is currently re…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma [Phase 1, Phase 2]
This document outlines an ongoing Phase 1/2 dose-escalation and dose-expansion trial of MDX2003 in multiple lymphoma types, including Walden…
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers [Phase 1]
Phase 1 study of oral LOXO-338 in advanced blood cancers is ongoing, with status listed as active but not recruiting.